Li, Nan <br/><br/>
Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.  [electronic resource] 

 -  Biomaterials  Apr 2013 
 - 3366-80 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1878-5905 
<br/><br/><label>Standard No.: </label>10.1016/j.biomaterials.2013.01.055  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenosine Triphosphate--metabolism<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Caspases--metabolism<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Cytochromes c--metabolism<br/>Drug Delivery Systems<br/>Drug Resistance, Neoplasm--drug effects<br/>Enzyme Activation--drug effects<br/>Epirubicin--pharmacology<br/>Female<br/>Humans<br/>Indazoles--pharmacology<br/>Liposomes--chemistry<br/>Membrane Potential, Mitochondrial--drug effects<br/>Mice<br/>Mice, Inbred BALB C<br/>Mitochondria--drug effects<br/>Myeloid Cell Leukemia Sequence 1 Protein<br/>Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Reactive Oxygen Species--metabolism<br/>Signal Transduction--drug effects<br/>Xenograft Model Antitumor Assays<br/>bcl-2-Associated X Protein--metabolism